Deanna L. Kroetz, PhD, BS Pharm

Dean, Professor

College Administration

Pharmaceutics and Pharmacology

Email: kroetz.3@osu.edu
Phone: 614-292-2266
Office: 223 Parks Hall
Links: Professional Website

Professional Interests

The Kroetz laboratory studies the molecular basis of interindividual variability in chemotherapy-induced peripheral neuropathy (CIPN). Genome-wide genotyping and exome sequencing are used to identify genetic biomarkers of peripheral neurotoxicity. Novel genes and pathways are functionally interrogated in human iPSC-derived sensory neurons to define the molecular basis for genetic association findings and therapeutic strategies for reversal or prevention are investigated.

Research & Expertise:

Biography

Deanna Kroetz is Dean and Professor of The Ohio State University College of Pharmacy. Prior to joining Ohio State in late 2023, she was Professor and Chair of Bioengineering and Therapeutic Sciences and the Jere E. Goyan Presidential Chair for the Advancement of Pharmacy in the School of Pharmacy at the University of California San Francisco. She received her B.S. degree in Pharmacy from Ohio State University and her Ph.D. in Pharmaceutics from the University of Washington, under the mentorship of Dr. René Levy. Dr. Kroetz was a PRAT Fellow in the Laboratory of Molecular Carcinogenesis at the National Cancer Institute under the mentorship of Dr. Frank Gonzalez before joining the faculty at the University of California San Francisco.

Her research aims to understand the mechanisms underlying interindividual variation in drug response and toxicity, with a current focus on chemotherapy-induced peripheral neuropathy (CIPN). Her laboratory uses genomic approaches such as genome-wide genotyping and exome sequencing to identify genetic biomarkers of chemotherapy toxicity. Functional genomic studies use an induced pluripotent stem cell derived sensory neuron model to characterize genetic variants of interest and to understand the molecular basis for involvement of novel genes and pathways in neurotoxicity. They are also studying the role of the multidrug resistance protein MRP4 in immunosensitivity and response to immunotherapies.

Dr. Kroetz served as the Director of the Pharmaceutical Sciences and Pharmacogenomics Graduate Program at UCSF from 2010 – 2019 and the Deputy Editor-in-Chief of Clinical and Translational Science from 2015-2025. She is currently President Elect of the American Society for Clinical Pharmacology and Therapeutics.

Education

1990-1993 - Postdoctoral Fellow, National Cancer Institute, Laboratory of Molecular Carcinogenesis
1990 - PhD, University of Washington
1985 - BS Pharm, The Ohio State University College of Pharmacy

Honors

2026 - Honorary Doctorate, University of Southern Denmark
2025 - Elected Member, National Academy of Medicine
2025 - Gruber Lecturer in Pharmacology, Thomas Jefferson Sidney Kimmel Medical School
2022 - Rawls-Palmer Progress in Medicine Award, American Society for Clinical Pharmacology & Therapeutics ASCPT
2020 - Named a University of Washington School of Pharmacy Alumni Legend
2020 - Bristol-Myers Squibb Mentorship in Clinical Pharmacology Award, American College of Clinical Pharmacology
2020 - Jere E. Goyan Presidential Chair, Advancement of Pharmacy
2020 - Deans Apple Award for Teaching, UCSF School of Pharmacy
2019 - Mentor Award, American Society for Clinical Pharmacology and Therapeutics
2018 - Elected Fellow, American Association for the Advancement of Science
2019 - Deans Apple Award for Teaching, UCSF School of Pharmacy
2018 - Dean's Apple Award for Teaching, UCSF School of Pharmacy
2018 - Distinguished Alumnus Award for Excellence in Pharmaceutical Sciences and Research, University of Washington School of Pharmacy
2016 - Dean's Apple Award for Teaching, UCSF School of Pharmacy
2014 - Judith Pool Award for Mentoring, Northern California Association for Women in Science
2011 - Dean's Apple Award for Teaching, UCSF School of Pharmacy
2009 - Dean's Apple Award for Teaching, UCSF School of Pharmacy
2008 - Elected Fellow, American Association of Pharmaceutical Scientists, American Association of Pharmaceutical Scientists
2008 - Named to Faculty of 1000, Pharmacology, Pharmacology
2002 - Elected Fellow, High Blood Pressure Research Council of the American Heart Association, American Heart Association
2002 - Leon I. Goldberg Young Investigator Award, American Society for Clinical Pharmacology and Therapeutics
1996 - American Association of Pharmaceutical Scientists Young Investigator Award in Pharmacokinetics, Phar, American Association of Pharmaceutical Scientists
1995 - Josephine S. Failer Alumni Award, The Ohio State University College of Pharmacy
1991-93 - Pharmacology Research Associate Training (PRAT) Fellowship
1987-90 - National Institute of Health Training Grant Trainee
1985 - Ohio State University Presidential Scholar
1985 - Eli Lilly Company Achievement Award
1985 - Cum Laude Graduate Ohio State University College of Pharmacy
1984 - National Pharmaceutical Council Internship
1984 - Mortar Board Honor Society
1984 - Rho Chi National Pharmacy Honorary

Publications

Data from A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma, . 2026 Jun | preprint. doi: 10.1158/1078-0432.c.8542448.
Supplementary Item S1 from A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma, . 2026 Jun | preprint. doi: 10.1158/1078-0432.32709674.
Supplementary Tables S1-S10 from A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma, . 2026 Jun | preprint. doi: 10.1158/1078-0432.32709671.
A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma, Clinical Cancer Research. 2026 May | journal-article. doi: 10.1158/1078-0432.CCR-25-4080.
Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration‐Resistant Prostate Cancer, Clinical and Translational Science. 2025 Dec | journal-article. doi: 10.1111/cts.70425.
Modeling mechanisms of chemotherapy-induced peripheral neuropathy and chemotherapy transport using induced pluripotent stem cell-derived sensory neurons, Neuropharmacology. 2024 Nov | journal-article. doi: 10.1016/j.neuropharm.2024.110062.
Effect of Antioxidants in Medicinal Products on Intestinal Drug Transporters, Pharmaceutics. 2024 May | journal-article. doi: 10.3390/pharmaceutics16050647.
Structural basis of prostaglandin efflux by MRP4, Nature Structural & Molecular Biology. 2024 Apr | journal-article. doi: 10.1038/s41594-023-01176-4.
Paclitaxel- and vincristine-induced neurotoxicity and drug transport in sensory neurons, . 2023 Feb | preprint. doi: 10.1101/2023.02.07.527432.
Host variation in type i interferon signaling genes (MX1), C-C chemokine receptor type 5 gene, and major histocompatibility complex class i alleles in treated HIV+ noncontrollers predict viral reservoir size, AIDS. 2023 Jan | journal-article. doi: 10.1097/QAD.0000000000003428.
Inhibition of muscarinic receptor signaling protects human enteric inhibitory neurons against platin chemotherapy toxicity, bioRxiv. 2023 Jan | other. doi: 10.1101/2023.03.08.531806.
Structural Basis of Prostaglandin Efflux by MRP4, . 2022 Dec | preprint. doi: 10.1101/2022.12.22.521501.
Mechanistic insights into the pathogenesis of microtubule‐targeting agent‐induced peripheral neuropathy from pharmacogenetic and functional studies, Basic & Clinical Pharmacology & Toxicology. 2022 Jan | journal-article. doi: 10.1111/bcpt.13654.
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients, British Journal of Cancer. 2022 Jan | journal-article. doi: 10.1038/s41416-021-01557-w.
Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients (British Journal of Cancer, (2021), 10.1038/s41416-021-01557-w), British Journal of Cancer. 2022 Jan | journal-article. doi: 10.1038/s41416-021-01617-1.
New and Emerging Research on Solute Carrier and ATP Binding Cassette Transporters in Drug Discovery and Development: Outlook From the International Transporter Consortium, Clinical Pharmacology and Therapeutics. 2022 Jan | journal-article. doi: 10.1002/cpt.2627.
POLYMORPHISMS OF DRUG TRANSPORTERS AND CLINICAL RELEVANCE, Drug Transporters: Molecular Characterization and Role in Drug Disposition: Third Edition. 2022 Jan | book-chapter. doi: 10.1002/9781119739883.ch18.
GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer, Clinical and Translational Science. 2021 Jan | journal-article. doi: 10.1111/cts.12937.
Host variation in type I interferon signaling genes (MX1), CCR5Δ32, and MHC class I alleles in treated HIV+ non-controllers predict viral reservoir size, bioRxiv. 2021 Jan | other. doi: 10.1101/2021.10.31.466670.
Human Induced Pluripotent Stem Cell Derived Sensory Neurons are Sensitive to the Neurotoxic Effects of Paclitaxel, Clinical and Translational Science. 2021 Jan | journal-article. doi: 10.1111/cts.12912.
In-depth triacylglycerol profiling using MS³ Q-Trap mass spectrometry, Analytica Chimica Acta. 2021 Jan | journal-article. doi: 10.1016/j.aca.2021.339023.
Interaction of Commonly Used Oral Molecular Excipients with P-glycoprotein, AAPS Journal. 2021 Jan | journal-article. doi: 10.1208/s12248-021-00631-8.
Role for Drug Transporters in Chemotherapy-Induced Peripheral Neuropathy, Clinical and Translational Science. 2021 Jan | journal-article. doi: 10.1111/cts.12915.
Genome-Wide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy, medRxiv. 2020 Jan | other. doi: 10.1101/2020.04.23.20076208.
Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy, Clinical Pharmacology and Therapeutics. 2020 Jan | journal-article. doi: 10.1002/cpt.1958.
P-Glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Patients With Cancer, Clinical Pharmacology and Therapeutics. 2020 Jan | journal-article. doi: 10.1002/cpt.1847.
A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance), Clinical Pharmacology and Therapeutics. 2019 Jan | journal-article. doi: 10.1002/cpt.1241.
A practical first step using needs assessment and a survey approach to implementing a clinical pharmacogenomics consult service, JACCP Journal of the American College of Clinical Pharmacy. 2019 Jan | journal-article. doi: 10.1002/jac5.1062.
Apical shear stress enhanced organic cation transport in Human OCT2/MATE1-transfected madin-darby canine kidney cells involves ciliary sensing, Journal of Pharmacology and Experimental Therapeutics. 2019 Jan | journal-article. doi: 10.1124/jpet.118.255026.
Efficient estimation of grouped survival models, BMC Bioinformatics. 2019 Jan | journal-article. doi: 10.1186/s12859-019-2899-x.
Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug–Drug Interaction and Associated Biomarker Levels in Healthy Volunteers, Clinical and Translational Science. 2019 Jan | journal-article. doi: 10.1111/cts.12625.
Reversible inhibition of efflux transporters by hydrogel microdevices, European Journal of Pharmaceutics and Biopharmaceutics. 2019 Jan | journal-article. doi: 10.1016/j.ejpb.2019.10.007.
Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle, Clinical Pharmacology and Therapeutics. 2019 Jan | journal-article. doi: 10.1002/cpt.1211.
ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia, Pharmacogenomics Journal. 2018 Jan | journal-article. doi: 10.1038/tpj.2016.75.
Bevacizumab-induced hypertension: Clinical presentation and molecular understanding, Pharmacology and Therapeutics. 2018 Jan | journal-article. doi: 10.1016/j.pharmthera.2017.08.012.
CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies, AIDS Research and Human Retroviruses. 2018 Jan | journal-article. doi: 10.1089/aid.2018.0062.
Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review, Clinical Pharmacokinetics. 2018 Jan | journal-article. doi: 10.1007/s40262-017-0563-z.
Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro, British Journal of Clinical Pharmacology. 2018 Jan | journal-article. doi: 10.1111/bcp.13467.
Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci, Pharmacogenetics and Genomics. 2018 Jan | journal-article. doi: 10.1097/FPC.0000000000000318.
Identification of a genomic region between SLC29A1 and HsP90AB1 associated with risk of bevacizumab-induced hypertension: CALGB 80405 (Alliance), Clinical Cancer Research. 2018 Jan | journal-article. doi: 10.1158/1078-0432.CCR-17-1523.
Rare variants in the ABCG2 promoter modulate in vivo activity, Drug Metabolism and Disposition. 2018 Jan | journal-article. doi: 10.1124/dmd.117.079541.
ABCG2 regulatory single-nucleotide polymorphisms alter in vivo enhancer activity and expression, Pharmacogenetics and Genomics. 2017 Jan | journal-article. doi: 10.1097/FPC.0000000000000312.
Genetic advances uncover mechanisms of chemotherapy-induced peripheral neuropathy, Clinical Pharmacology and Therapeutics. 2017 Jan | journal-article. doi: 10.1002/cpt.590.
In vivo hepatic enhancer elements in the human ABCG2 locus, Drug Metabolism and Disposition. 2017 Jan | journal-article. doi: 10.1124/dmd.116.072033.
Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell lines, Pharmacogenomics Journal. 2017 Jan | journal-article. doi: 10.1038/tpj.2015.93.
Best Practices for Clinical and Translational Research and Implementation, Clinical and Translational Science. 2016 Jan | journal-article. doi: 10.1111/cts.12411.
Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans, AIDS. 2016 Jan | journal-article. doi: 10.1097/QAD.0000000000001124.
Metabolomic and Genome-wide Association Studies Reveal Potential Endogenous Biomarkers for OATP1B1, Clinical Pharmacology and Therapeutics. 2016 Jan | journal-article. doi: 10.1002/cpt.434.
Multidrug resistance-associated protein 4 is a determinant of arsenite resistance, Oncology Reports. 2016 Jan | journal-article. doi: 10.3892/or.2015.4343.
Pharmacogenetic discovery in CALGB (alliance) 90401 and mechanistic validation of a VAC14 polymorphism that increases risk of docetaxel-induced neuropathy, Clinical Cancer Research. 2016 Jan | journal-article. doi: 10.1158/1078-0432.CCR-15-2823.
Transforming Translation: Impact of Clinical and Translational Science, Clinical and Translational Science. 2016 Jan | journal-article. doi: 10.1111/cts.12380.
PharmGKB summary: Very important pharmacogene information for human leukocyte antigen B, Pharmacogenetics and Genomics. 2015 Jan | journal-article. doi: 10.1097/FPC.0000000000000118.
Pharmacoethnicity in paclitaxel-induced sensory peripheral neuropathy, Clinical Cancer Research. 2015 Jan | journal-article. doi: 10.1158/1078-0432.CCR-15-0133.
SOX11 identified by target gene evaluation of miRNAs differentially expressed in focal and non-focal brain tissue of therapy-resistant epilepsy patients, Neurobiology of Disease. 2015 Jan | journal-article. doi: 10.1016/j.nbd.2015.02.025.
ABCC4 is regulated by microRNA-124a and microRNA-506, Biochemical Pharmacology. 2014 Jan | journal-article. doi: 10.1016/j.bcp.2013.10.017.
Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing: 2014 update, Clinical Pharmacology and Therapeutics. 2014 Jan | journal-article. doi: 10.1038/clpt.2014.38.
Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention, Journal of Clinical Pharmacology. 2014 Jan | journal-article. doi: 10.1002/jcph.248.
Genomic architecture of pharmacological efficacy and adverse events, Pharmacogenomics. 2014 Jan | journal-article. doi: 10.2217/pgs.14.144.
PharmGKB summary: Abacavir pathway, Pharmacogenetics and Genomics. 2014 Jan | journal-article. doi: 10.1097/FPC.0000000000000040.
Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance), Pharmacogenomics Journal. 2014 Jan | journal-article. doi: 10.1038/tpj.2014.2.
Response to "cYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers", Clinical Pharmacology and Therapeutics. 2014 Jan | journal-article. doi: 10.1038/clpt.2013.239.
Abacavir pharmacogenetics - From initial reports to standard of care, Pharmacotherapy. 2013 Jan | journal-article. doi: 10.1002/phar.1278.
Association of cyp2c9*2 with bosentan-induced liver injury, Clinical Pharmacology and Therapeutics. 2013 Jan | journal-article. doi: 10.1038/clpt.2013.143.
Epoxyeicosatrienoic acids prevent cisplatin-induced renal apoptosis through a p38 mitogen-activated protein kinase-regulated mitochondrial pathway, Molecular Pharmacology. 2013 Jan | journal-article. doi: 10.1124/mol.113.088302.
Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression, Pharmacogenomics Journal. 2013 Jan | journal-article. doi: 10.1038/tpj.2012.20.
Genome-wide association studies in pharmacogenomics: Successes and lessons, Pharmacogenetics and Genomics. 2013 Jan | journal-article. doi: 10.1097/FPC.0b013e32833d7b45.
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of paclitaxel-induced sensory peripheral neuropathy, Clinical Cancer Research. 2013 Jan | journal-article. doi: 10.1158/1078-0432.CCR-12-2618.
Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: Towards addressing the missing heritability in pharmacogenetic phenotypes?, Pharmacogenetics and Genomics. 2013 Jan | journal-article. doi: 10.1097/FPC.0b013e32836533a5.
OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis, Pharmacogenetics and Genomics. 2013 Jan | journal-article. doi: 10.1097/FPC.0b013e3283620c3b.
The Pharmacogenomics of Membrane Transporters Project, Pharmacogenomics of Human Drug Transporters: Clinical Impacts. 2013 Jan | book-chapter. doi: 10.1002/9781118353240.ch4.
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance), Pharmacogenetics and Genomics. 2013 Jan | journal-article. doi: 10.1097/FPC.0b013e32835b16d8.
A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101, Clinical Cancer Research. 2012 Jan | journal-article. doi: 10.1158/1078-0432.CCR-12-1590.
Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor κB signaling, Journal of Pharmacology and Experimental Therapeutics. 2012 Jan | journal-article. doi: 10.1124/jpet.111.191247.
Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing, Clinical Pharmacology and Therapeutics. 2012 Jan | journal-article. doi: 10.1038/clpt.2011.355.
Discovery of regulatory elements in human ATP-binding cassette transporters through expression quantitative trait mapping, Pharmacogenomics Journal. 2012 Jan | journal-article. doi: 10.1038/tpj.2011.8.
Ethical aspects of participation in the Database of Genotypes and Phenotypes of the National Center for Biotechnology Information: The Cancer and Leukemia Group B Experience, Cancer. 2012 Jan | journal-article. doi: 10.1002/cncr.27515.
In vitro metabolism of piperaquine is primarily mediated by CYP3A4, Xenobiotica. 2012 Jan | journal-article. doi: 10.3109/00498254.2012.693972.
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 1-98 trial, Journal of the National Cancer Institute. 2012 Jan | journal-article. doi: 10.1093/jnci/djs304.
Cerivastatin, genetic variants, and the risk of rhabdomyolysis, Pharmacogenetics and Genomics. 2011 Jan | journal-article. doi: 10.1097/FPC.0b013e328343dd7d.
Contribution of aquaporin 9 and multidrug resistance-associated protein 2 to differential sensitivity to arsenite between primary cultured chorion and amnion cells prepared from human fetal membranes, Toxicology and Applied Pharmacology. 2011 Jan | journal-article. doi: 10.1016/j.taap.2011.09.006.
Exploiting the complexity of the genome and transcriptome using pharmacogenomics towards personalized medicine., Genome biology. 2011 Jan | journal-article. doi: 10.1186/gb-2011-12-1-301.
Functional characterization of liver enhancers that regulate drug-associated transporters, Clinical Pharmacology and Therapeutics. 2011 Jan | journal-article. doi: 10.1038/clpt.2010.353.
Letter to the editor, Protein Science. 2011 Jan | journal-article. doi: 10.1002/pro.555.
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein), Pharmacogenetics and Genomics. 2011 Jan | journal-article. doi: 10.1097/FPC.0b013e3283385a1c.
Functional hot spots in human ATP-binding cassette transporter nucleotide binding domains, Protein Science. 2010 Jan | journal-article. doi: 10.1002/pro.491.
Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): Functional characterization and interindividual variability, Pharmacogenetics and Genomics. 2010 Jan | journal-article. doi: 10.1097/FPC.0b013e3283349eb0.
The pharmacogenomics of membrane transporters project: Research at the interface of genomics and transporter pharmacology, Clinical Pharmacology and Therapeutics. 2010 Jan | journal-article. doi: 10.1038/clpt.2009.226.
A survey of integral α-helical membrane proteins, Journal of Structural and Functional Genomics. 2009 Jan | journal-article. doi: 10.1007/s10969-009-9069-8.
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics, Journal of Clinical Oncology. 2009 Jan | journal-article. doi: 10.1200/JCO.2008.20.6300.
Evolutionary conservation of vertebrate blood-brain barrier chemoprotective mechanisms in drosophila, Journal of Neuroscience. 2009 Jan | journal-article. doi: 10.1523/JNEUROSCI.5564-08.2009.
Genetic Polymorphisms in ABC Transporters, ABC Transporters and Multidrug Resistance. 2009 Jan | book-chapter. doi: 10.1002/9780470495131.ch15.
Genetic variation in the proximal promoter of ABC and SLC superfamilies: Liver and kidney specific expression and promoter activity predict variation, PLoS ONE. 2009 Jan | journal-article. doi: 10.1371/journal.pone.0006942.
The University of California Pharmacogenomics Center: At the interface of genomics, biologicalmechanisms and drug therapy, Pharmacogenomics. 2009 Jan | journal-article. doi: 10.2217/PGS.09.119.
Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation, Journal of Pharmacology and Experimental Therapeutics. 2008 Jan | journal-article. doi: 10.1124/jpet.108.142398.
Nicotine metabolism in pregnant and nonpregnant rabbits, Nicotine and Tobacco Research. 2008 Jan | journal-article. doi: 10.1080/14622200802238878.
Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults, PLoS ONE. 2008 Jan | journal-article. doi: 10.1371/journal.pone.0003981.
Substrate-dependent effects of human ABCB1 coding polymorphisms, Journal of Pharmacology and Experimental Therapeutics. 2008 Jan | journal-article. doi: 10.1124/jpet.107.135194.
The effects of ABCB1 3′-untranslated region variants on mRNA stability, Drug Metabolism and Disposition. 2008 Jan | journal-article. doi: 10.1124/dmd.107.017087.
The human multidrug resistance protein 4 (MRP4, ABCC4): Functional analysis of a highly polymorphic gene, Journal of Pharmacology and Experimental Therapeutics. 2008 Jan | journal-article. doi: 10.1124/jpet.108.136523.
ABCB1 pharmacogenetics: Progress, pitfalls, and promise, Clinical Pharmacology and Therapeutics. 2007 Jan | journal-article. doi: 10.1038/sj.clpt.6100052.
Adherence-resistance relationships to combination HIV antiretroviral therapy, Current HIV/AIDS Reports. 2007 Jan | journal-article. doi: 10.1007/s11904-007-0010-0.
Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: Implications for malaria treatment in Africa, Clinical Pharmacology and Therapeutics. 2007 Jan | journal-article. doi: 10.1038/sj.clpt.6100122.
Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor α, Drug Metabolism and Disposition. 2007 Jan | journal-article. doi: 10.1124/dmd.106.013839.
Function-altering SNPs in the human multidrug transporter gene ABCB1 identified using a Saccharomyces-based assay, PLoS Genetics. 2007 Jan | journal-article. doi: 10.1371/journal.pgen.0030039.
Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein, Journal of Antimicrobial Chemotherapy. 2007 Jan | journal-article. doi: 10.1093/jac/dkm135.
Irinotecan-induced diarrhea: Functional significance of the polymorphic ABCC2 transporter protein, Clinical Pharmacology and Therapeutics. 2007 Jan | journal-article. doi: 10.1038/sj.clpt.6100019.
Lack of support for a role for RLIP76 (RALBP1) in response to treatment or predisposition to epilepsy, Epilepsia. 2007 Jan | journal-article. doi: 10.1111/j.1528-1167.2007.00926.x.
Response to Janigro et al. [4], Epilepsia. 2007 Jan | journal-article. doi: 10.1111/j.1528-1167.2007.01155_5.x.
The Pharmacogenetics Research Network: From SNP discovery to clinical drug response, Clinical Pharmacology and Therapeutics. 2007 Jan | journal-article. doi: 10.1038/sj.clpt.6100087.
CYP4 isoform specificity in the ω-hydroxylation of phytanic acid, a potential route to elimination of the causative agent of Refsum's disease, Journal of Pharmacology and Experimental Therapeutics. 2006 Jan | journal-article. doi: 10.1124/jpet.106.104976.
Induction of renal cytochrome P450 arachidonic acid epoxygenase activity by dietary γ-linolenic acid, Journal of Pharmacology and Experimental Therapeutics. 2006 Jan | journal-article. doi: 10.1124/jpet.105.098558.
Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor α-dependent repression of cyclin D1, Arteriosclerosis, Thrombosis, and Vascular Biology. 2006 Jan | journal-article. doi: 10.1161/01.ATV.0000242013.29441.81.
MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer., Drug metabolism and pharmacokinetics. 2006 Jan | journal-article. doi: 10.2133/dmpk.21.126.
PharmGKB submission update: IV. PMT submissions of genetic variations in ATP-binding cassette transporters to the PharmGKB network, Pharmacological Reviews. 2006 Jan | journal-article. doi: 10.1124/pr.58.1.1.
PharmGKB submission update: V. PMT submissions of genetic variation in SLC22 family transporters, Pharmacological Reviews. 2006 Jan | journal-article. doi: 10.1124/pr.58.1.2.
PharmGKB submission update: VI. PMT submissions of genetic variations in neurotransmitter transporters (SLC6, SLC17, and SLC18) to the PharmGKB network, Pharmacological Reviews. 2006 Jan | journal-article. doi: 10.1124/pr.58.1.3.
Role for drug transporters beyond tumor resistance: Hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity, Journal of Clinical Oncology. 2006 Jan | journal-article. doi: 10.1200/JCO.2006.07.2355.
Differential renal gene expression in prehypertensive and hypertensive spontaneously hypertensive rats, American Journal of Physiology - Renal Physiology. 2005 Jan | journal-article. doi: 10.1152/ajprenal.00354.2004.
Drug-metabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests, Clinical Pharmacology and Therapeutics. 2005 Jan | journal-article. doi: 10.1016/j.clpt.2005.08.013.
Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability, Pharmacogenetics and Genomics. 2005 Jan | journal-article. doi: 10.1097/01.fpc.0000178311.02878.83.
Regulation and inhibition of arachidonic acid ω-hydroxylases and 20-HETE formation, Annual Review of Pharmacology and Toxicology. 2005 Jan | book. doi: 10.1146/annurev.pharmtox.45.120403.100045.
Catalytic Activity and Isoform-Specific Inhibition of Rat Cytochrome P450 4F Enzymes, Journal of Pharmacology and Experimental Therapeutics. 2004 Jan | journal-article. doi: 10.1124/jpet.103.059626.
Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1), Pharmaceutical Research. 2004 Jan | journal-article. doi: 10.1023/B:PHAM.0000029276.21063.0b.
Vascular localization of soluble epoxide hydrolase in the human kidney, American Journal of Physiology - Renal Physiology. 2004 Jan | journal-article. doi: 10.1152/ajprenal.00165.2003.
Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1, Proceedings of the National Academy of Sciences of the United States of America. 2003 Jan | journal-article. doi: 10.1073/pnas.0730858100.
Natural variation in human membrane transporter genes reveals evolutionary and functional constraints, Proceedings of the National Academy of Sciences of the United States of America. 2003 Jan | journal-article. doi: 10.1073/pnas.0730857100.
No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects, Clinical Pharmacology and Therapeutics. 2003 Jan | journal-article. doi: 10.1016/S0009-9236(03)00234-0.
Notes of the American Society for clinical pharmacology and therapeutics: A message from the ASCPT Membership Committee chairperson, Clinical Pharmacology and Therapeutics. 2003 Jan | journal-article. .
Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene, Pharmacogenetics. 2003 Jan | journal-article. doi: 10.1097/00008571-200308000-00006.
Antihypertensive effect of mechanism-based inhibition of renal arachidonic acid ω-hydroxylase activity, American Journal of Physiology - Regulatory Integrative and Comparative Physiology. 2002 Jan | journal-article. doi: 10.1152/ajpregu.00522.2001.
Candidate gene approach for pharmacogenetic studies, Pharmacogenomics. 2002 Jan | journal-article. doi: 10.1517/14622416.3.1.47.
Covalent attachment of the heme prosthetic group in the CYP4F cytochrome P450 family, Biochemistry. 2002 Jan | journal-article. doi: 10.1021/bi025527y.
Cytochrome P450 pathways of arachidonic acid metabolism, Current Opinion in Lipidology. 2002 Jan | journal-article. doi: 10.1097/00041433-200206000-00007.
MDR1 reference sequence and reference function [1], Clinical Pharmacology and Therapeutics. 2002 Jan | journal-article. doi: 10.1067/mcp.2002.125561.
Antimalarial drugs are not substrates of human P-glycoprotein, Clinical Pharmacology and Therapeutics. 2001 Jan | journal-article. .
Ethnic differences in the allele frequency of polymorphisms in the MDR1 gene, Clinical Pharmacology and Therapeutics. 2001 Jan | journal-article. .
Transport and disposition of nicotine in the human placenta, Clinical Pharmacology and Therapeutics. 2001 Jan | journal-article. .
Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney, Molecular Pharmacology. 2000 Jan | journal-article. .
Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system, Drug Metabolism and Disposition. 2000 Jan | journal-article. .
Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids, Circulation Research. 2000 Jan | journal-article. doi: 10.1161/01.RES.87.11.992.
Structural determination of the substrate specificities and regioselectivities of the rat and human fatty acid ω-hydroxylases, Archives of Biochemistry and Biophysics. 2000 Jan | journal-article. doi: 10.1006/abbi.1999.1504.
Structure activity relationship of human microsomal epoxide hydrolase inhibition by amide and acid analogues of valproic acid, Pharmaceutical Research. 2000 Jan | journal-article. doi: 10.1023/A:1007577600088.
Docosahexaenoic acid is an antihypertensive nutrient that affects aldosterone production in SHR, Proceedings of the Society for Experimental Biology and Medicine. 1999 Jan | journal-article. doi: 10.1046/j.1525-1373.1999.d01-51.x.
PPARα-dependent induction of renal CYP4A expression by fasting, Clinical Pharmacology and Therapeutics. 1999 Jan | journal-article. doi: 10.1016/S0009-9236(99)80283-5.
The effects of a diet rich in docosahexaenoic acid on organ and vascular fatty acid composition in spontaneously hypertensive rats, Prostaglandins Leukotrienes and Essential Fatty Acids. 1999 Jan | journal-article. doi: 10.1054/plef.1999.0102.
Inhibition of renal arachidonic acid co-hydroxylase activity with ABT reduces blood pressure in the SHR, American Journal of Physiology. 1998 Jan | journal-article. .
Inhibition of renal arachidonic acid ω-hydroxylase activity with ABT reduces blood pressure in the SHR, American Journal of Physiology - Regulatory Integrative and Comparative Physiology. 1998 Jan | journal-article. doi: 10.1152/ajpregu.1998.275.2.r426.
Peroxisome proliferator-activated receptor controls the hepatic CYP4A induction adaptive response to starvation and diabetes, Journal of Biological Chemistry. 1998 Jan | journal-article. doi: 10.1074/jbc.273.47.31581.
Structure-function relationships of human liver cytochromes P450 3A: Aflatoxin B1 metabolism as a probe, Biochemistry. 1998 Jan | journal-article. doi: 10.1021/bi980895g.
Developmentally regulated expression of the CYP4A genes in the spontaneously hypertensive rat kidney, Molecular Pharmacology. 1997 Jan | journal-article. doi: 10.1124/mol.52.3.362.
Targeted disruption of the α isoform of the peroxisome proliferator- activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators, Molecular and Cellular Biology. 1995 Jan | journal-article. doi: 10.1128/MCB.15.6.3012.
Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation, Biochemical Pharmacology. 1994 Jan | journal-article. doi: 10.1016/0006-2952(94)90071-X.
Carbamazepine‐Valnoctamide Interaction in Epileptic Patients: In Vitro/In Vivo Correlation, Epilepsia. 1993 Jan | journal-article. doi: 10.1111/j.1528-1157.1993.tb02117.x.
Glycosylation-Dependent Activity of Baculovirus-Expressed Human Liver Carboxylesterases: cDNA Cloning and Characterization of Two Highly Similar Enzyme Forms, Biochemistry. 1993 Jan | journal-article. doi: 10.1021/bi00094a018.
In vivo and in vitro correlation of microsomal epoxide hydrolase inhibition by progabide, Clinical Pharmacology & Therapeutics. 1993 Jan | journal-article. doi: 10.1038/clpt.1993.180.
Interaction of Carbamazepine with Valnoctamide: Data 'in vitro' and in patients with epilepsy,INTERAZIONE DELLA CARBAMAZEPINA CON LA VALNOCTAMIDE: DATI 'IN VITRO' ED IN PAZIENTI CON EPILESSIA, Bollettino - Lega Italiana contro l'Epilessia. 1993 Jan | journal-article. .
Measurement of in vivo microsomal epoxide hydrolase activity in white subjects, Clinical Pharmacology & Therapeutics. 1993 Jan | journal-article. doi: 10.1038/clpt.1993.26.